Young adults, blacks, cisgender women, and people in rural areas, as well as people on Medicaid, were less likely to persist on PrEP.
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.
Most people who could benefit from pre-exposure prophylaxis are not accessing it, the U.S. Centers for Disease Control and Prevention revealed at this year's Conference on Retroviruses and Opportunistic Infections.
When is a pre-exposure prophylaxis (PrEP) failure actually a provider failure? And how do we tell the difference?
The CDC has released new data at the Conference on Retroviruses and Opportunistic Infections (CROI) estimating that only a small percentage of people most at risk for HIV infection have actually been prescribed pre-exposure prophylaxis (PrEP).
No increase in poor birth outcomes with PrEP used throughout pregnancy in the Partners Demonstration project.
Brief, empowering messaging around pre-exposure prophylaxis (PrEP) can lead to better medication adherence, new research has found.
For one pharmacy in Seattle, the pharmacist plays multiple roles, doing everything from the HIV testing, to the patient education, to the prescribing of PrEP.
On behalf of TheBodyPRO.com, Terri Wilder, M.S.W., spoke with Elske Hoornenborg, M.D., who presented a case study of HIV transmission despite good adherence to pre-exposure prophylaxis (PrEP) and no drug resistance, at CROI 2017.
"If there is compelling evidence that [a certain agent] works, we stop the trial straight away and let the world know what's going on," says Deborah Donnell, Ph.D.